First-Ever human test of promising CMV vaccine shows early safety results
NCT ID NCT05089630
Summary
This study tested a new vaccine designed to prevent cytomegalovirus (CMV) infections in healthy adults aged 18-50. Researchers gave 339 participants different dose levels of the vaccine to check for safety and see if it triggered an immune response. The main goal was to monitor side effects and measure how well the body produced antibodies against CMV.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Anaheim, California, 92806, United States
-
GSK Investigational Site
Long Beach, California, 90806, United States
-
GSK Investigational Site
Los Angeles, California, 90017, United States
-
GSK Investigational Site
Hallandale, Florida, 33009, United States
-
GSK Investigational Site
Miami, Florida, 33143, United States
-
GSK Investigational Site
Lexington, Kentucky, 40536-0084, United States
-
GSK Investigational Site
Dearborn, Michigan, 48127, United States
-
GSK Investigational Site
Springfield, Missouri, 65802, United States
-
GSK Investigational Site
Lincoln, Nebraska, 68510, United States
-
GSK Investigational Site
Omaha, Nebraska, 68134, United States
-
GSK Investigational Site
Las Vegas, Nevada, 89109, United States
-
GSK Investigational Site
Newark, New Jersey, 07103, United States
-
GSK Investigational Site
Secaucus, New Jersey, 07094, United States
-
GSK Investigational Site
New York, New York, 10065, United States
-
GSK Investigational Site
Austin, Texas, 78744-1645, United States
-
GSK Investigational Site
Cedar Park, Texas, 78613, United States
-
GSK Investigational Site
Galveston, Texas, 77573, United States
-
GSK Investigational Site
Puyallup, Washington, 98371, United States
Conditions
Explore the condition pages connected to this study.